Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 3/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | HINT1 | P49773 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | TK1 | P04183 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29187215 | 0.87 | ADORA3 (0.43) | PNPHINT1ADORA3HPGDCYP3A4 | |
| SCHEMBL1904551 | 0.79 | PNP (0.44) | PNPXDHTAAR1HINT1ADORA3 | |
| SCHEMBL8004041 | 0.78 | LMNA (0.42) | MAPT | |
| SCHEMBL7764660 | 0.78 | PNP (0.49) | PNPXDHTAAR1HINT1ADORA3 | |
| SCHEMBL13626438 | 0.78 | ADORA3 (0.47) | PNPHINT1ADORA3HPGDCYP3A4 | |
| SCHEMBL16258667 | 0.78 | ADORA3 (0.47) | PNPHINT1ADORA3HPGDCYP3A4 | |
| SCHEMBL116166 | 0.78 | ADORA3 (0.47) | PNPHINT1ADORA3HPGDCYP3A4 | |
| SCHEMBL18537395 | 0.78 | ADORA3 (0.47) | PNPHINT1ADORA3HPGDCYP3A4 | |
| SCHEMBL3018983 | 0.78 | ADORA3 (0.47) | PNPHINT1ADORA3HPGDCYP3A4 | |
| SCHEMBL18537401 | 0.78 | ADORA3 (0.47) | PNPHINT1ADORA3HPGDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6849723-B2 | Oligonucleotide analogs having modified dimers | ISIS PHARMACEUTICALS, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20030181693-A1 | Oligonucleotide analogs having modified dimers | COOK PHILLIP DAN (US) | 2003-09-25 | — | — | US | disclosed |
| EP-0977767-A4 | AMINOOXY-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2003-04-23 | — | — | EP | disclosed |
| EP-1102783-A4 | AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS INC (US) | 2002-07-31 | — | — | EP | disclosed |
| EP-1102783-A1 | AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000008042-A1 | AMINOOXY-MODIFIED NUCLEOSIDIC COMPOUNDS AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
| WO-2000008214-A1 | OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED DIMERS | ISIS PHARMACEUTICALS, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
| EP-0977767-A1 | AMINOOXY-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2000-02-09 | — | — | EP | disclosed |
| WO-1998035978-A9 | AMINOOXY-MODIFIED OLIGONUCLEOTIDES | — | 1999-01-14 | — | — | WO | disclosed |
| WO-1998035978-A1 | AMINOOXY-MODIFIED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181693-A1 | Oligonucleotide analogs having modified dimers | RNASEL, ADAR, RNGTT | PNP 54/4885XDH 2784/4885TAAR1 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.